A Randomized, Double-blind, Parallel-group, Multi-center Study to Investigate the Pharmacodynamics and Pharmacokinetics of a Combined Oral Contraceptive Containing Levonorgestrel (LNG) and Ethinylestradiol (EE) When Given Together With Vilaprisan Over 3 Months in Healthy Women of Reproductive Age
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2018
At a glance
- Drugs Vilaprisan (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Endometriosis; Uterine leiomyoma
- Focus Therapeutic Use
- Sponsors Bayer
- 05 Jan 2018 Planned primary completion date changed from 10 May 2018 to 10 Jun 2018.
- 10 Aug 2017 Status changed from not yet recruiting to recruiting.
- 11 Jul 2017 New trial record